Market news
Capricor (CAPR) spikes on new deramiocel HOPE-3 24-month Duchenne data ahead of Nov.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Capricor Therapeutics is back in focus after fresh analyst work led to sharply revised price targets, with some models now pointing to fair value estimates as high as US$27.00 from US$4.38. These shifts reflect a wide spread in analyst opinion as investors weigh the extended FDA action date for deramiocel, the mixed advisory committee outcome, and new upper limb function data that some research views as important. Read on to see what is driving the competing narratives around Capricor...
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
– Late-Breaking Data to Include HOPE-3 Delayed-Start and Natural History Analyses Submitted in the Recent Major Amendment to the Deramiocel BLA – – PDUFA Target Action Date of November 22, 2026 – SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that data from HOPE-3 and its open-label extension (OLE) of Deramiocel, the Compan
Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Capricor Therapeutics (CAPR) has an average rating of overweight and mean price target of $31.78, ac
Capricor Therapeutics, Inc. (NASDAQ:CAPR) has gained another opportunity to make the case for deramiocel, its experimental cell therapy for Duchenne muscular dystrophy. The FDA extended its review by three months after accepting new 24-month clinical data and additional analyses from the company. The submission supports a refined proposed indication focused on upper limb function, which […]
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Newsfile Press Release.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Capricor Therapeutics (NASDAQ:CAPR) shares rose 2. 5% in pre-market trading to $10.
Piper Sandler upgraded Capricor to ‘Overweight’ from ‘Neutral’ and sharply raised the price target to $25, a roughly 150% upside potential from current levels.
Capricor Therapeutics (CAPR) has an average rating of overweight and mean price target of $31.78, ac
This is the newest page. Registered accounts read further back.